Akorn to re-launch erythromycin ophthalmic ointment

Links shared publicly online about this topic.

  • 1,221
    total visits

Akorn to re-launch erythromycin ophthalmic ointment

osnsupersite.com

LAKE FOREST, Ill. — The U.S. Food and Drug Administration has approved Akorn's supplemental abbreviated new drug application to once again distri

View full resource at osnsupersite.com

Tags: Drug, FDA, Ophthalmology

  • Share

Most Recently Shared on April 23, 2010 at 7:15 am By:

OSNSuperSite The OSN SuperSite

Akorn to re-launch erythromycin ophthalmic ointment: http://ow.ly/1BUj5 — #ophthalmology #business #news

2 years ago...

Akorn Announces Launch Of Erythromycin Ophthalmic Ointment USP 1 G

medicalnewstoday.com — “Akorn, Inc. (NASDAQ:AKRX) a niche generic pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Erythromycin Ophthalmic OintmentView full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on September 19, 2010 at 1:05 pm By:

mnt_eyehealth MNT Eye Health Health News

Akorn Announces Launch Of Erythromycin Ophthalmic Ointment USP 1 G http://mnt.to/3JYR #eyehealth

2 years ago...

Akorn Announces Launch Of Erythromycin Ophthalmic Ointment USP 1 G - QualityPoint Technologies

qualitypointtech.net — “Akorn, Inc. (NASDAQ:AKRX) a niche generic pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted approval of the Company's Erythromycin Ophthalmic Ointment USP 1 g as a supplement to the Company's already approved Abbreviated New Drug Application (ANDA) for Erythromycin Ophthalmic Ointment USP 3.5 g. The company has begun shipping the product to its customers.View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on September 19, 2010 at 12:25 pm By:

MedicalFeed MedicalFeed Health News Feed

Akorn Announces Launch Of Erythromycin Ophthalmic Ointment USP 1 G: Akorn, Inc. (NASDAQ:AKRX) a niche generic phar... http://bit.ly/beUF9C

2 years ago...

Advertisement